Saturday — November 14, 2015
|
Welcome! |
Ophthalmology Times welcomes ophthalmic professionals from around the world to Las Vegas. Our four-day coverage of this year's meeting of the American Academy of Ophthalmology begins today and includes the latest research findings and clinical news of interest to readers. Enjoy the meeting! |
TOP STORIES |
Results from the Diabetic Retinopathy Clinical Research Network Protocol S provide evidence for the first major advance in the treatment of proliferative diabetic retinopathy (PDR) in more than 40 years, said Jeffrey Gross, MD. » Read the results |
Swept-source, microscope-integrated, ocular coherence tomography (SS-MIOCT) is a new investigational technology for real-time intraoperative imaging of the cornea and anterior segment, said Terry Kim, MD. » Learn more
|
The prospect of an expanding armamentarium of corneal inlays for presbyopia correction is an exciting development, said Jay A. Pepose, MD, PhD. » Read more |
Pre-existing dry eye can affect the outcomes of excimer laser refractive and cause significant postoperative morbidity as well as patient dissatisfaction. Therefore, preoperative screening for dry eye is critical, said Michael B. Raizman, MD. » Find out why |
FROM THE SHOW FLOOR |
The availability of a new cataract surgery platform from Abbott Medical Optics (AMO) marks the second phacoemulsification system launched by the company in the United States this year. » Find out more |
Diopsys Inc. introduced a tabletop version of its electroretinography (ERG) and visual evoked potential (VEP) testing technology (ARGOS). » Learn more |
|
We welcome your feedback!
Please send your comments to:
Mark L. Dlugoss
Group Content Director
UBM Medica Eyecare Group
mark.dlugoss@ubm.com |
DISCLAIMER:
This information has been independently developed and provided by the editors of Ophthalmology Times. The sponsors do not endorse and are not responsible for the accuracy of the content or for practices or standards of non-sponsor sources. These articles may discuss regimens that have not been approved by the FDA. For full prescribing information including indications, contraindications, warnings, precautions, and adverse experiences, please see the appropriate manufacturer's product circular. |
|